Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321

Viswatej Avutu, Aaron R. Weiss, Damon R. Reed, Safia K. Ahmed, Wendy A. Allen-Rhoades, Yen Lin E. Chen, Lara E. Davis, Bree R. Eaton, Douglas S. Hawkins, Danny J. Indelicato, Shreyaskumar R. Patel, R. Lor Randall, Denise K. Reinke, Richard F. Riedel, Thomas J. Scharschmidt, Katherine A. Thornton, Dian Wang, Katherine A. Janeway, Lisa M. Kopp

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

ARST1321, a trial of patients with advanced soft tissue sarcoma, was the first National Clinical Trials Network study codeveloped by pediatric and adult consortia with two treatment cohorts. We report on the findings of a survey to identify barriers to enrolling adolescent and young adult patients (15-39 years) onto the nonchemotherapy arm. The survey response rate was 31% with a 70% completion rate. Common identified reasons for low accrual in order of decreasing frequency included insufficient funding, lack of study awareness or interest, competing trials, toxicity concerns, philosophical differences in the therapy backbone, and regulatory and infrastructure barriers. Clinical Trials.gov ID: NCT02180867.

Original languageEnglish (US)
Pages (from-to)328-332
Number of pages5
JournalJournal of Adolescent and Young Adult Oncology
Volume11
Issue number3
DOIs
StatePublished - Jun 1 2022

Keywords

  • clinical trials
  • cooperative groups
  • enrollment barriers
  • NCTN
  • survey

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology

Fingerprint

Dive into the research topics of 'Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321'. Together they form a unique fingerprint.

Cite this